Clinical Trials

Phase EARLY_PHASE1 Recruiting

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT07205315 2026-05-27

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

28 enrolled

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Hemolytic, Autoimmune, Burkitt Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07609030 2026-05-27

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

Phase NA Recruiting

90 enrolled

LymphoidPlasma cell

Multiple Myeloma, Lymphoma, B-Cell

NCT04088864 2026-05-26

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Phase 1 Completed

10 enrolled

Lymphoma, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06742996 2026-05-22

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Phase 3 Recruiting

300 enrolled

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT05615636 2026-05-20

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Phase 2 Recruiting

36 enrolled

Hodgkin Disease, Lymphoma, B-Cell

NCT05826535 2026-05-20

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

270 enrolled

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT03774654 2026-05-18

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

13 enrolled

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05773040 2026-05-18

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

Phase 1 Recruiting

33 enrolled

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, B-Cell

NCT07593482 2026-05-18

FC-BALANCE

92 enrolled

Phase 3 Active not recruiting

Lymphoma, B-Cell

NCT04662255 2026-05-15

BRUIN-MCL-321

500 enrolled

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT05397496 2026-05-15

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

61 enrolled

Phase 2 Not yet recruiting

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07588698 2026-05-15

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

20 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03570892 2026-05-14

BELINDA

Phase 3 Completed

330 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06564038 2026-05-14

Soundtrack-E

408 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06879340 2026-05-14

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

Phase 1 Recruiting

54 enrolled

Phase 1 Not yet recruiting

Burkitt Lymphoma, Lymphoma, B-Cell

NCT07451054 2026-05-14

CD45BE-HSPC + CART-45 Cells

42 enrolled

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT05272384 2026-05-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Phase 1 Recruiting

32 enrolled

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Phase 1 Not yet recruiting

48 enrolled

DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT07101328 2026-05-13

BAF_FRontier-1

215 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07584850 2026-05-13

Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

9 enrolled

Lymphoma, B-Cell

NCT07584889 2026-05-13

CAR-p40-T

10 enrolled

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

54 enrolled 12 charts

Phase EARLY_PHASE1 Active not recruiting

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

40 enrolled

Lymphoma, B-Cell

NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Phase 2 Recruiting

20 enrolled

Phase 3 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06230224 2026-05-11

OLYMPIA-4

216 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06634589 2026-05-11

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT05421663 2026-05-08

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

439 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05784441 2026-05-08

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

21 enrolled

Recurrence, Lymphoma, B-Cell

NCT07123454 2026-05-08

Lumi-NHL

91 enrolled

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT06242834 2026-05-07

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

32 enrolled

Phase EARLY_PHASE1 Suspended

Lymphoma, B-Cell

NCT06662227 2026-05-07

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

30 enrolled

Leukemia, B-Cell, Lymphoma, B-Cell

NCT03349450 2026-05-06

SPiReL

Phase 2 Completed

25 enrolled 18 charts

LymphoidSarcoma

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT05092451 2026-05-06

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances